Results 21 to 30 of about 6,967 (165)

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care [PDF]

, 2017
Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterised by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations.
Alastair Kent, Albert C M Ong, Brenda de Coninck, Denis Clément, Dorien Peters, Elena Levtchenko, Hendrik Van Poppel, Joost P H Drenth, José Luis Górriz, Klemens Budde, Lorenzo E Derchi, Marianna Eleftheroudi, null null, null null, null null, Olivier Devuyst, Raymond Vanholder, Richard Sandford, Ron T Gansevoort, Tess Harris, Tevfik Ecder, Vicente E Torres, Yves Pirson   +22 more
core   +6 more sources

Tolvaptan in ADPKD Patients With Very Low Kidney Function [PDF]

, 2021
Introduction: Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) in TEMPO 3:4 and REPRISE trials.
Chapman, Arlene B, Gansevoort, Ron T, Japes, Hina, Lee, Jennifer, Nourbakhsh, Ali, Ouyang, John, Perrone, Ronald D, Torres, Vicente E, Wang, Tao   +8 more
core   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Successful treatment of congestive heart failure with concomitant administration of tolvaptan to enhance the effects of furosemide [PDF]

, 2013
Tolvaptan (TLV), which is an antagonist to the vasopressin V2 receptor, was approved by Japanese authorities for the treatment of “volume overload in heart failure when adequate response is not obtained with other diuretics (e.g. loop diuretics)”.
Daida, Hiroyuki, Nishizaki, Yuji, Sesoko, Masahiro, Yamagami, Shinichiro, Yamashita, Haruyo   +4 more
core   +1 more source

Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.
Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera, Raquel López‐Vilella, Víctor Donoso Trenado, María Peris‐Fernández, Paula Carmona, Amparo Soldevila, Sergi Tormo, Ramón Devesa, María Jesús Montero Hernández, Luis Martínez Dolz, Julio Hernández Jaras, Pilar Sánchez‐Pérez, Luis Almenar‐Bonet   +12 more
wiley   +1 more source

Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair

ESC Heart Failure, EarlyView.
Abstract Aims Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge‐to‐edge mitral valve repair (M‐TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients.
Ai Kagase, Masanori Yamamoto, Takahiro Tokuda, Ryotaku Kawahata, Hiroto Nishio, Tetsuro Shimura, Ryo Yamaguchi, Mitsuru Sago, Yuki Izumi, Mike Saji, Masahiko Asami, Yusuke Enta, Masaki Nakashima, Shinichi Shirai, Masaki Izumo, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Junichi Yamaguchi, Toru Naganuma, Hiroki Bouta, Yohei Ohno, Masahiro Yamawaki, Hiroshi Ueno, Kazuki Mizutani, Daisuke Hachinohe, Toshiaki Otsuka, Shunsuke Kubo, Kentaro Hayashida, OCEAN‐Mitral Investigators   +30 more
wiley   +1 more source

Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients [PDF]

, 2020
Tolvaptan efficacy for heart failure has a large interindividual variation. This study aimed to evaluate the influence of CYP3A5 and ABCB1 genotypes on tolvaptan pharmacokinetics and their relationships with plasma markers of CYP3A activity and ...
Akutsu, Shunta, Hoshikawa, Kohei, Kawakami, Junichi, Maekawa, Yuichiro, Naito, Takafumi, Saotome, Masao   +5 more
core   +1 more source

Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial

ESC Heart Failure, EarlyView.
Abstract Aims Functional mitral regurgitation (FMR) is associated with adverse outcomes in patients with heart failure, and current guideline‐directed medical therapy (GDMT) offers limited efficacy in managing FMR. This study aims to evaluate the therapeutic impact of the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in patients with ...
Zhuoshan Huang, Rui Fan, Shaozhao Zhang, Junlin Zhong, Yiquan Huang, Peihan Xie, Shanshan Yin, Xiaomin Ye, Xinghao Xu, Rihua Huang, Zhenyu Xiong, Yue Guo, Menghui Liu, Yifen Lin, Suhua Li, Xiaoxian Qian, Jinlai Liu, Xiaodong Zhuang, Xinxue Liao   +18 more
wiley   +1 more source

Fármacos que atuam modulando a ação da vasopressina [PDF]

, 2015
Projeto de Pós-Graduação/Dissertação apresentado à Universidade Fernando Pessoa como parte dos requisitos para obtenção do grau de Mestre em Ciências FarmacêuticasA vasopressina, também é designada por hormona antidiurética (ADH), a nível renal aumenta a
Cardoso, Ana Catarina Santos
core  

Identification and Characterization of an Activating F229V Substitution in the V2 Vasopressin Receptor in an Infant with NSIAD [PDF]

, 2012
Gain-of-function mutations in the gene encoding the V2 vasopressin receptor (V2R) cause nephrogenic syndrome of inappropriate antidiuresis. To date, reported mutations lead to the substitution of arginine 137 by either a cysteine or leucine (R137C/L ...
Abrol, Ravinder, Bichet, Daniel G., Bouvier, Michel, Carpentier, Eric, Goddard, William A., III, Greenbaum, Larry A., Rochdi, Driss   +6 more
core   +1 more source